TerminatedNot Applicable

LMWH to Prevent Preeclampsia and Fetal Growth Restriction

Started 2002-01

Plain-language summary

The objective of this trial will be to determine whether prophylactic low-molecular weight heparin therapy in pregnant women with the heterozygous Factor V Leiden and G20210A prothrombin gene mutations thrombophilia and a history of severe preeclampsia and/or severe fetal growth restriction reduces the risk of the composite outcome of preeclampsia, fetal growth restriction, or both.

Who can participate

Age range20 Years – 40 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Previous severe preeclampsia * Previous severe fetal growth restriction * Heterozygous Factor V Leiden * Heterozygous G20210A prothrombin gene mutations Exclusion Criteria: * renal disease * chronic hypertension * preexisting diabetes mellitus * homozygosity for Factor V Leiden * homozygosity for prothrombin G20210A mutation * hyperhomocysteinemia * protein C deficency * protein S deficency * antithrombin deficiency * positive anticardiolipin antibodies * positive lupus anticoagulant

Trial details

NCT IDNCT00260520

SponsorUniversity of Florence

Sponsor typeOTHER

Study typeOBSERVATIONAL

View on ClinicalTrials.gov More Preeclampsia trials